论文部分内容阅读
目的了解氟桂利嗪添加治疗难治性癫痫患者的临床疗效与逆转多药耐药基因(MDR1)表达的关系。方法42例难治性癫痫患者在原抗癫痫药不变的基础上应用氟桂利嗪添加冶疗,12周后评价临床疗效。同时用ELISA法检测患者氟桂利嗪添加治疗前后血清P-糖蛋白(PGP),并和正常对照组10人比较。结果氟桂利嗪添加治疗难治性癫痫的总有效率达52.5%。难治性癫痫患者血清PGP水平显著高于正常对照组,且治疗后血清PGP水平较治疗前明显下降,差异均有统计学意义(分别P<0.01和<0.05)。结论氟桂利嗪添加治疗难治性癫痫有效,其抗癫痫机制可能与逆转PGP表达有关。
Objective To investigate the clinical efficacy of flunarizine in the treatment of patients with refractory epilepsy and its relationship with the reversal of multidrug resistance gene (MDR1) expression. Methods Forty-two patients with refractory epilepsy were treated with flunarizine on the basis of the same antiepileptic drugs, and the clinical effects were evaluated after 12 weeks. At the same time, serum P-glycoprotein (PGP) before and after the treatment with flunarizine was detected by ELISA and compared with the normal control group. Results Flunarizine added to treat refractory epilepsy the total effective rate of 52.5%. Serum PGP levels in patients with refractory epilepsy were significantly higher than those in the normal control group, and serum PGP levels after treatment were significantly lower than those before treatment (P <0.01 and <0.05, respectively). Conclusion Flunarizine added effective treatment of intractable epilepsy, its anti-epileptic mechanism may be related to the reversal of PGP expression.